TP53 and B-cell chronic lymphocytic leukemia: Despite these advancements, TP53 aberrations continue to exert a deleterious influence on the prognosis of patients with CLL undergoing chemoimmunotherapy, underscoring the critical role of genetic markers in the stratification and selection of therapeutic strategies.